Literature DB >> 22815044

Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations.

Marilena Celano1, Marialuisa Sponziello, Giovanni Tallini, Valentina Maggisano, Rocco Bruno, Mariavittoria Dima, Enrico Di Oto, Adriano Redler, Cosimo Durante, Rosario Sacco, Sebastiano Filetti, Diego Russo.   

Abstract

Autonomously functioning thyroid nodules (AFTN) are known to receive an increased blood influx necessary to sustain their high rate of growth and hormone production. Here, we investigated the expression of hematic and lymphatic vases in a series of 20 AFTN compared with the contralateral non-tumor tissues of the same patients, and the transcript levels of proteins involved in the control of vascular proliferation, including the vascular endothelial growth factor (VEGF) and platelet-derived growth factors (PDGF) and their receptors and the endothelial nitric oxide synthase (eNOS). In parallel, the expression of the differentiation markers sodium/iodide symporter (NIS), thyroperoxidase (TPO), thyroglobulin (Tg), and TSH receptor (TSHR) was also investigated. The data were further analyzed comparing subgroups of tumors with or without mutations in the TSHR gene. Analysis by means of CD31 and D2-40 immunostaining showed in AFTN an increased number of hematic, but not lymphatic, vessels in parallel with an enhanced proliferation rate shown by increased Ki67 staining. Quantitative RT-PCR analysis revealed an increase of VEGF, VEGFR1 and 2, PDGF-A, PDGF-B, and eNOS expression in tumor versus normal tissues. Also, higher transcript levels of NIS, TPO, and Tg were detected. Comparison of the two subgroups of samples revealed only few differences in the expression of the genes examined. In conclusion, these data demonstrate an increased expression of angiogenesis-related factors associated with an enhanced proliferation of hematic, but not lymphatic, vessels in AFTNs. In this context, the presence of TSHR mutations may only slightly influence the expression of pro-angiogenic growth factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815044     DOI: 10.1007/s12020-012-9747-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A novel mutation in the thyrotropin (TSH) receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH.

Authors:  D Russo; C Betterle; F Arturi; E Chiefari; M E Girelli; S Filetti
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

3.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors:  Rebecca S Bahn Chair; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal:  Thyroid       Date:  2011-04-21       Impact factor: 6.568

4.  A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis.

Authors:  D Russo; M G Wong; G Costante; E Chiefari; P A Treseler; F Arturi; S Filetti; O H Clark
Journal:  Thyroid       Date:  1999-01       Impact factor: 6.568

5.  TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation.

Authors:  D Russo; G Costante; R Bruno; M Sponziello; G Tamburrano; M Dima; R Sacco; L Giacomelli; C Durante; S Filetti
Journal:  Endocrine       Date:  2011-08-24       Impact factor: 3.633

Review 6.  Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.

Authors:  Katarina L Kojic; Stefan L Kojic; Sam M Wiseman
Journal:  Expert Rev Anticancer Ther       Date:  2012-03       Impact factor: 4.512

7.  Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology.

Authors:  S Deleu; Y Allory; A Radulescu; I Pirson; N Carrasco; B Corvilain; I Salmon; B Franc; J E Dumont; J Van Sande; C Maenhaut
Journal:  Thyroid       Date:  2000-02       Impact factor: 6.568

8.  Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.

Authors:  G Viglietto; A Romano; G Manzo; G Chiappetta; I Paoletti; D Califano; M G Galati; V Mauriello; P Bruni; C T Lago; A Fusco; M G Persico
Journal:  Oncogene       Date:  1997-11-27       Impact factor: 9.867

9.  Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.

Authors:  N Garcia de la Torre; I Buley; J A H Wass; H E Turner
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

10.  Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma.

Authors:  Julian E Donckier; Luc Michel; Monique Delos; Xavier Havaux; Ronald Van Beneden
Journal:  Clin Endocrinol (Oxf)       Date:  2006-06       Impact factor: 3.478

View more
  5 in total

1.  VEGF and GM-CSF levels in nodular thyroid diseases.

Authors:  Birsen Bilgici; Gulcin C Ecemis; Ozgur K Tuncel; Ilkay K Bayrak; Elif K Kan; Aysegul Atmaca
Journal:  Endocrine       Date:  2013-04-28       Impact factor: 3.633

Review 2.  Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.

Authors:  Rimas J Orentas; Jessica Nordlund; Jianbin He; Sivasish Sindiri; Crystal Mackall; Terry J Fry; Javed Khan
Journal:  Front Oncol       Date:  2014-06-10       Impact factor: 6.244

Review 3.  Is there still a role for thyroid scintigraphy in the workup of a thyroid nodule in the era of fine needle aspiration cytology and molecular testing?

Authors:  Rodrigo Moreno-Reyes; Aglaia Kyrilli; Maria Lytrivi; Carole Bourmorck; Rayan Chami; Bernard Corvilain
Journal:  F1000Res       Date:  2016-04-27

4.  Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population.

Authors:  Rui Liu; Lifeng Ning; Xiaoli Liu; Huiping Zhang; Yaqin Yu; Shangchao Zhang; Wenwang Rao; Jieping Shi; Hui Sun; Qiong Yu
Journal:  Oncotarget       Date:  2017-02-28

5.  Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies.

Authors:  Haixia Guan; Danielle Matonis; Gianluca Toraldo; Stephanie L Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-25       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.